Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073058 | 0.85 | PARP1 (0.52) | PARP1ALDH1A1MAPTTSHRGAA | |
| SCHEMBL14072971 | 0.84 | GAA (0.61) | ALDH1A1MAPTTSHRGAAMAOA | |
| SCHEMBL14073372 | 0.83 | KMT2A (0.54) | PARP1ALDH1A1MAPTTSHRKDM4E | |
| SCHEMBL14073116 | 0.82 | PARP1 (0.62) | PARP1ALDH1A1MAPTTSHRMAOA | |
| SCHEMBL14073370 | 0.79 | HPGD (0.64) | PARP1ALDH1A1MAPTTSHRMAOA | |
| SCHEMBL9130576 | 0.78 | PARP1 (0.60) | PARP1ALDH1A1MAPTTSHRGAA | |
| SCHEMBL14073051 | 0.78 | PARP1 (0.70) | PARP1ALDH1A1MAPTTSHRMAOA | |
| SCHEMBL14073056 | 0.77 | NPC1 (0.52) | PARP1ALDH1A1MAPTTSHRGAA | |
| SCHEMBL14073622 | 0.77 | POLB (0.59) | ALDH1A1MAPTKMT2APOLB | |
| SCHEMBL4295364 | 0.76 | PARP1 (0.65) | PARP1ALDH1A1MAPTTSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | PARP1 327/4885ALDH1A1 714/4885MAPT 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.